2022 American Transplant Congress
Cost-Effectiveness of Transplanting Hepatitis C Donor Hearts Into Hepatitis C Uninfected Recipients
*Purpose: To examine the clinical impact and cost-effectiveness of hepatitis C viremic (HCV+) heart organ donation in the United States.*Methods: We used a microsimulation model…2022 American Transplant Congress
Twelve Month Outcomes of Kidney Transplantation from Hepatitis C Viremic Deceased Donors to Aviremic Recipients
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The utilization of Hepatitis C viremic (HCV+) deceased donor kidneys for uninfected recipients allows for increased opportunities for organ transplantation. Initial studies have indicated…2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…2022 American Transplant Congress
Long-Term Follow Up of Solid Organ Transplantation Using Hepatitis C Virus Positive Donor for Hepatitis C Virus Negative Recipients
*Purpose: To determine the effects of transplanting an HCV + solid organ to an uninfected patient who is on the transplant waiting list. Outcomes include…2022 American Transplant Congress
The Oncological Influences of Pre- and Post-Transplant Sustained Viral Response in Liver Transplant for Hepatocellular Carcinoma
*Purpose: Chronic hepatitis C infection (HCV) is one of the most common causes of hepatocellular carcinoma. After emerging direct-acting agents (DAA), the success rate of…2022 American Transplant Congress
Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review
*Purpose: The advent of combination direct-acting antiviral (DAA) agents has improved the ability to treat hepatitis C virus (HCV) infections. As a result, utilization of…2022 American Transplant Congress
Hepatitis C (HCV) Positive Recipients and/or Donors in Pancreas Transplantation – A Registry Analysis
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: Pancreas transplantation (PT) is the best long-term option for patients with labile diabetes and end-stage-renal disease. The mortality on the waitlist is high; patients…2022 American Transplant Congress
Hepatitis C Positive Kidney Transplant Into Hepatitis C Negative Recipients
*Purpose: Kidney transplantation is the treatment of choice in end stage renal disease (ESRD). In 2018, 5% to 8% of eligible adults died while on…2021 American Transplant Congress
Comparison of Outcomes of Hepatitis C Virus (hcv) Nucleic Acid (nat) Positive Donor Between Hcv-naïVe and Hcv + Recpients – A Donor Mate Analysis
University of Virginia, Charlottesville, VA
*Purpose: Despite a growing mismatch between organ need and supply, organs from HCV+ donors were only offered to HCV+ recipients (HCV R+) to avoid complications…2021 American Transplant Congress
Not Always as it Seems: Lack of Hepatitis C Virus Transmission from Nucleic Acid Testing Positive Deceased Donors
1Medicine, University of Virginia, Charlottesville, VA, 2University of Virginia, Charlottesville, VA
*Purpose: Hepatitis C virus (HCV) + organs are increasingly use to transplant HCV naive candidates with good short-term outcomes. HCV transmission with HCV nucleic acid…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 28
- Next Page »